Tag Archives: pharmaceuticals
I’m not, ordinarily, a fan of big companies’ annual reports. There’s way too much puffery, and far too little substance. However, I’m intrigued by an exception this year. Pfizer (NYSE: PFE), under the gun from regulators, investors and various other constituencies, has put out a remarkable little booklet called Ten Questions. In the report, the company tries to address, head-on, some of the sharpest criticisms leveled against itself and the pharmaceutical industry.
In the midst of this new bull market, one group of stocks is writhing in pain: pharmaceuticals. Are we hearing a death knell — or is it a dinner bell?
I’m inclined to press the button for Option #2. Granted, all the major drug makers are facing issues with patent expirations in the next couple of years.